The University of Chicago Header Logo
Last Name


Michael H. Davidson to United States Food and Drug Administration

This is a "connection" page, showing publications Michael H. Davidson has written about United States Food and Drug Administration.

Connection Strength
  1. Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008 Mar; 6(3):391-409.
    View in: PubMed
    Score: 0.084
  2. Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am J Cardiol. 2006 Apr 17; 97(8A):32C-43C.
    View in: PubMed
    Score: 0.073
  3. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005 Jan 01; 95(1):120-2.
    View in: PubMed
    Score: 0.067
  4. Davidson M, Kanter M, Catapano A, Saidman C. What kinds of data should be available to probe the effects of nutrients, food supplements or vitamins on serum lipoprotein levels and/or atherosclerosis? Am J Cardiol. 1998 Apr 23; 81(8A):80F-83F.
    View in: PubMed
    Score: 0.042
  5. Borzelleca JF, Cheney M, Davidson MH, Degnan FH, Derfler PS, Forbes AL, Glinsmann W, Heckman JH, Miller SA, Rulis AM, Masten LW. Panel discussion: what is the future of macronutrient substitutes in North America? Regul Toxicol Pharmacol. 1996 Feb; 23(1 Pt 2):S51-9.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.